TY - JOUR
T1 - Mycophenolate mofetil
T2 - Effects on clinical transplantation
AU - Holt, Curtis D.
AU - Sievers, Theodore M.
AU - Ghobrial, Rafik M.
AU - Rossi, Steven J.
AU - Goss, John A.
AU - McDiarmid, Sue V.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.
AB - Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.
UR - http://www.scopus.com/inward/record.url?scp=0031729484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031729484&partnerID=8YFLogxK
U2 - 10.2165/00063030-199810050-00004
DO - 10.2165/00063030-199810050-00004
M3 - Review article
C2 - 18020609
AN - SCOPUS:0031729484
SN - 1173-8804
VL - 10
SP - 373
EP - 384
JO - BioDrugs
JF - BioDrugs
IS - 5
ER -